Thrombocytosis [clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece]
clinicaltrials:NCT00509899clinicaltrials:NCT00722527Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) [clinicaltrials:NCT00882414]The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection [clinicaltrials:NCT01194349]clinicaltrials:NCT01787552A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders [clinicaltrials:NCT02125318]Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions [clinicaltrials:NCT02308787]
condition [clinicaltrials_vocabulary:condition]
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction [clinicaltrials:NCT00025415]Imatinib Mesylate in Treating Patients With Myelofibrosis [clinicaltrials:NCT00039416]Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia [clinicaltrials:NCT00047190]clinicaltrials:NCT00052520Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00089011]Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [clinicaltrials:NCT00112593]clinicaltrials:NCT00175838A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [clinicaltrials:NCT00202644]clinicaltrials:NCT00227591Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00357305]clinicaltrials:NCT00381550Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00397813]clinicaltrials:NCT00413634Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders [clinicaltrials:NCT00433862]Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome [clinicaltrials:NCT00445744]Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00489203]clinicaltrials:NCT00509899A Safety Study of XL019 in Adults With Myelofibrosis [clinicaltrials:NCT00522574]Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments [clinicaltrials:NCT00567502]Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [clinicaltrials:NCT00586651]Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [clinicaltrials:NCT00588991]Correlative Biomarker Study in Patients With Myeloproliferative Disorders [clinicaltrials:NCT00665067]Familial Myeloproliferative Disorders [clinicaltrials:NCT00666289]Research Tissue Bank [clinicaltrials:NCT00666549]CEP-701 (Lestaurtinib) in Myelofibrosis [clinicaltrials:NCT00668421]clinicaltrials:NCT00715247Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia [clinicaltrials:NCT00718159]clinicaltrials:NCT00722527clinicaltrials:NCT00726232A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis [clinicaltrials:NCT00745550]A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia [clinicaltrials:NCT00866762]Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) [clinicaltrials:NCT00882414]clinicaltrials:NCT00890747Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases [clinicaltrials:NCT00910728]Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [clinicaltrials:NCT00935987]clinicaltrials:NCT00946270Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis [clinicaltrials:NCT01014546]Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer [clinicaltrials:NCT01053494]Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia [clinicaltrials:NCT01065038]A Study in Myeloproliferative Disorders [clinicaltrials:NCT01134120]
condition browse [clinicaltrials_vocabulary:condition-browse]
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction [clinicaltrials:NCT00025415]Imatinib Mesylate in Treating Patients With Myelofibrosis [clinicaltrials:NCT00039416]Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia [clinicaltrials:NCT00047190]clinicaltrials:NCT00052520Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00089011]Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [clinicaltrials:NCT00112593]clinicaltrials:NCT00175838A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [clinicaltrials:NCT00202644]clinicaltrials:NCT00227591Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00357305]clinicaltrials:NCT00381550Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00397813]clinicaltrials:NCT00413634Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders [clinicaltrials:NCT00433862]Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome [clinicaltrials:NCT00445744]Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00489203]clinicaltrials:NCT00509899A Safety Study of XL019 in Adults With Myelofibrosis [clinicaltrials:NCT00522574]Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments [clinicaltrials:NCT00567502]Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [clinicaltrials:NCT00586651]Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [clinicaltrials:NCT00588991]Correlative Biomarker Study in Patients With Myeloproliferative Disorders [clinicaltrials:NCT00665067]Familial Myeloproliferative Disorders [clinicaltrials:NCT00666289]Research Tissue Bank [clinicaltrials:NCT00666549]CEP-701 (Lestaurtinib) in Myelofibrosis [clinicaltrials:NCT00668421]clinicaltrials:NCT00715247Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia [clinicaltrials:NCT00718159]clinicaltrials:NCT00722527clinicaltrials:NCT00726232A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis [clinicaltrials:NCT00745550]A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia [clinicaltrials:NCT00866762]Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) [clinicaltrials:NCT00882414]clinicaltrials:NCT00890747Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases [clinicaltrials:NCT00910728]Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [clinicaltrials:NCT00935987]clinicaltrials:NCT00946270Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis [clinicaltrials:NCT01014546]Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer [clinicaltrials:NCT01053494]Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia [clinicaltrials:NCT01065038]A Study in Myeloproliferative Disorders [clinicaltrials:NCT01134120]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Thrombocytosis [clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece]
Bio2RDF identifier
8559a0fc1bbb59ae34aa517707437ece
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece
identifier
clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece
title
Thrombocytosis
@en
type
label
Thrombocytosis [clinicaltrials_resource:8559a0fc1bbb59ae34aa517707437ece]
@en
Thrombocytosis